Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP19A1 | P11511 | 3/20 | 0.36 |
| ▸ | CNR2 | P34972 | 3/20 | 0.35 |
| ▸ | CNR1 | P21554 | 2/20 | 0.35 |
| ▸ | ESR1 | P03372 | 2/20 | 0.32 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18852713 | 0.98 | CNR2 (0.37) | CYP19A1CNR2CNR1ESR1ESR2 | |
| SCHEMBL18721019 | 0.98 | CNR2 (0.37) | CYP19A1CNR2CNR1ESR1ESR2 | |
| SCHEMBL22007446 | 0.98 | CYP19A1 (0.37) | CYP19A1CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19251185 | 0.96 | CNR2 (0.38) | CYP19A1CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19251056 | 0.96 | CNR2 (0.38) | CYP19A1CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL18935500 | 0.96 | CNR2 (0.38) | CYP19A1CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL19251174 | 0.96 | CNR2 (0.38) | CYP19A1CNR2CNR1TDP1L3MBTL1 | |
| SCHEMBL18382253 | 0.96 | CYP19A1 (0.38) | CYP19A1CNR2CNR1ESR1ESR2 | |
| SCHEMBL19251062 | 0.93 | CNR2 (0.36) | CYP19A1CNR2CNR1ESR1ESR2 | |
| SCHEMBL22169010 | 0.92 | CYP19A1 (0.36) | CYP19A1ESR1ESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-12-14 | — | — | US | disclosed |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | ENANTA PHARMACEUTICALS, INC. (US) | 2021-07-13 | — | — | US | disclosed |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2020-05-28 | — | — | US | disclosed |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | ENANTA PHARMACEUTICALS, INC. | 2019-07-25 | — | — | US | disclosed |
| US-9981901-B2 | IRE-1α inhibitors | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2018-05-29 | — | — | US | disclosed |
| US-9932341-B2 | Use of pyrazolopyrimidine derivatives for the treatment of PI3K-delta related disorders | INCYTE CORPORATION (US) | 2018-04-03 | — | — | US | disclosed |
| US-20170152206-A1 | IRE-1alpha INHIBITORS | FOSUN ORINOVE PHARMATECH, INC. (CN) | 2017-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170152206-A1 | IRE-1alpha INHIBITORS | XBP1, DDIT3, ERN1 | CYP19A1 2908/4885CNR2 4584/4885CNR1 3756/4885 |
| US-20190224188-A1 | SUBSTITUTED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HDGF, HAVCR2 | CYP19A1 884/4885CNR2 2890/4885CNR1 2120/4885 |
| US-11058678-B2 | Substituted heterocycles as antiviral agents | HCCS, HDGF, HAVCR2 | CYP19A1 884/4885CNR2 2890/4885CNR1 2120/4885 |
| US-11198693-B2 | Functionalized heterocycles as antiviral agents | HCCS, HAVCR2, HDGF | CYP19A1 867/4885CNR2 2902/4885CNR1 2040/4885 |
| US-20200165249-A1 | FUNCTIONALIZED HETEROCYCLES AS ANTIVIRAL AGENTS | HCCS, HAVCR2, HDGF | CYP19A1 867/4885CNR2 2902/4885CNR1 2040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.